Skip to main content

Table 2 The baseline characteristics in T2DM patients with various MTNR1B rs10830963 genotypes before treatment with nateglinide (n = 200)

From: Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

Parameters MTNR1B rs10830963 genotype P value
CC CG GG
N (men/women) 70(40/30) 90(48/42) 40(23/17) 0.850Δ
Age (years) 47.81 ± 10.82 48.01 ± 12.04 47.09 ± 13.92 0.921
BMI (kg/m2) 26.41 ± 3.24 25.43 ± 3.31 26.59 ± 4.11 0.104
WHR 0.92 ± 0.06 0.91 ± 0.06 0.92 ± 0.08 0.552#
FPG (mmol/L) 9.61 ± 2.01 9.91 ± 2.79 10.82 ± 1.79 0.034*
PPG (mmol/L) 15.36 ± 2.46 14.21 ± 4.39 14.69 ± 5.71 0.224
FINS (mU/L) 8.56 ± 5.39 7.37 ± 6.99 7.53 ± 6.39 0.477#
PINS (mU/L) 30.01 ± 17.10 28.11 ± 20.51 33.51 ± 17.49 0.320
HOMA-IR 3.27 ± 1.30 3.09 ± 3.21 4.01 ± 2.47 0.160
HbA1c (%) 9.71 ± 1.97 9.11 ± 2.62 9.95 ± 2.04 0.098
TG (mmol/L) 2.25 ± 1.38 2.31 ± 2.13 1.97 ± 1.52 0.596
TC (mmol/L) 5.21 ± 1.29 4.99 ± 1.31 5.49 ± 1.51 0.143
HDL-c (mmol/L) 1.28 ± 0.95 1.33 ± 0.59 1.41 ± 0.29 0.645
LDL-c (mmol/L) 3.45 ± 0.68 3.61 ± 1.19 3.80 ± 0.93 0.199#
  1. BMI body mass index, WHR waist to hip ratio, FPG fasting plasma glucose, PPG postprandial plasma glucose, FINS fasting serum insulin, PINS postprandial serum insulin, HOMA-IR homeostasis model assessment for insulin resistance, HbA1c hemoglobin A1c, TG triglyceride, TC total cholesterol, HDL-c high-density lipoprotein-cholesterol, LDL-c low-density lipoprotein-cholesterol
  2. Data are given as (mean ± SD). P values represent statistical differences among the three different genotypes by the one-way ANOVA. ΔP values are determined by the Pearson chi-square test. #P values are determined by the Kruskal–Wallis test. *P < 0.05